Net sales remained at zero, with a net loss of -1.56 million SEK and an equity ratio of 33.8%. A February rights issue raised 2 million SEK, and plans are underway to delist from Spotlight and seek $6 million USD from international investors for clinical studies.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.